How to Get Vyleesi (Bremelanotide) in North Carolina

What Is Vyleesi and Who Is It For?

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 specifically for acquired, generalized HSDD in premenopausal women [1]. It is not indicated for postmenopausal women, for men, or for enhancing sexual performance in people without a diagnosed desire disorder. The drug works on central nervous system pathways rather than on vascular mechanisms, which distinguishes it from phosphodiesterase-5 inhibitors used in male sexual dysfunction.

In the two key RECONNECT phase 3 trials (N=1,247 combined), women receiving bremelanotide 1.75 mg subcutaneously reported a statistically significant increase in satisfying sexual events (SSEs) compared to placebo. The mean increase was approximately 0.5 additional SSEs per month over placebo [2]. Desire scores on the Female Sexual Function Index (FSFI) also improved. About 25% of bremelanotide-treated patients experienced nausea, making it the most common adverse event, though it tended to diminish with repeated dosing.

The FDA label caps use at 8 doses per month and warns against use in patients with uncontrolled hypertension or known cardiovascular disease because bremelanotide can transiently raise blood pressure [1]. A brief blood pressure increase of roughly 6/3 mmHg was observed in trials, resolving within 12 hours.

North Carolina Telehealth Prescribing Rules for Vyleesi

North Carolina law permits telehealth prescribing of prescription medications, including bremelanotide. A valid patient-provider relationship can be established via synchronous video or audio visit under the North Carolina Medical Board's telemedicine policy, updated in 2021. This means a premenopausal woman in Raleigh, Charlotte, Asheville, or any other NC location can consult a licensed prescriber remotely and receive a Vyleesi prescription without an in-person office visit.

The prescriber must hold an active North Carolina medical license (or a qualifying interstate compact license). Nurse practitioners in North Carolina practice under a Collaborative Practice Agreement with a supervising physician, and this agreement must cover the prescribing of bremelanotide if an NP writes the prescription [3]. Physician assistants similarly require supervising physician authorization.

Telehealth platforms that operate in North Carolina typically verify licensure, confirm the HSDD diagnosis through a structured intake questionnaire and live consultation, review relevant labs, and then transmit the prescription electronically to a pharmacy. Turnaround from initial consultation to prescription transmission is often 24 to 72 hours.

Step-by-Step: Getting a Vyleesi Prescription in NC

The process follows a predictable clinical workflow. First, the patient completes a medical intake covering sexual health history, cardiovascular risk factors, current medications, and menstrual status. Second, a licensed prescriber conducts a synchronous consultation (video or phone) to confirm the HSDD diagnosis, which requires the disturbance to cause marked distress and not be better explained by a mental health condition, relationship factors, medication effects, or another medical condition [4].

Third, the prescriber orders baseline labs. These typically include a comprehensive metabolic panel, thyroid function (TSH, free T4), prolactin, and a pregnancy test. Some clinicians also check testosterone and DHEA-S to rule out hormonal contributors to low desire, though this is not universally required by guidelines [5]. A blood pressure reading within the prior 90 days is also standard given bremelanotide's transient pressor effect.

Fourth, after lab review and diagnosis confirmation, the prescriber transmits the prescription. The patient can fill it at a retail pharmacy stocking the branded autoinjector or at a 503A compounding pharmacy that prepares bremelanotide in injectable form.

Pharmacy Access: Retail vs. 503A Compounding in North Carolina

Branded Vyleesi is available as a single-dose, prefilled autoinjector (1.75 mg/0.3 mL). Retail pharmacies such as CVS, Walgreens, and independent pharmacies in North Carolina can order and dispense it, though not every location keeps it in stock. Patients may need to request a special order, which adds 2 to 5 business days.

North Carolina also licenses 503A compounding pharmacies under the NC Board of Pharmacy regulations. These pharmacies can compound bremelanotide from bulk pharmaceutical-grade powder when a valid patient-specific prescription exists. Compounded bremelanotide is often dispensed in multi-dose vials at lower per-dose cost than the branded autoinjector.

Key differences between the two options:

The branded autoinjector offers FDA-verified potency, a fixed 1.75 mg dose, and single-use convenience, but it carries a list price of approximately $950 for four autoinjectors (roughly $237 per dose) without insurance. Compounded bremelanotide from a 503A pharmacy may cost $50 to $150 per month depending on dose count, but it is not FDA-inspected at the product level and requires the patient to draw and inject from a vial using an insulin syringe.

Both options are legally available to NC residents. The prescriber's script dictates which route the patient takes. Some telehealth platforms partner directly with 503A pharmacies and ship compounded bremelanotide to North Carolina addresses, typically via cold-chain overnight or two-day delivery.

Insurance Coverage and Cost in North Carolina

Commercial insurance coverage for Vyleesi varies by plan. Many insurers classify it as a specialty drug on a high formulary tier, and prior authorization is nearly universal. The prior authorization process in North Carolina generally requires documentation of the HSDD diagnosis (per DSM-5 criteria), confirmation that the patient is premenopausal, evidence that the condition causes clinically significant distress, and proof that contributing factors like depression, medication side effects, or relationship conflict have been addressed or ruled out [6].

North Carolina Medicaid does not cover Vyleesi for HSDD. The NC Medicaid Preferred Drug List excludes bremelanotide from its formulary. Patients enrolled in NC Medicaid who want bremelanotide will need to pay out of pocket or use a compounded formulation.

Cosette Pharmaceuticals (the current marketer of Vyleesi) has offered a copay savings program that reduces out-of-pocket costs for commercially insured patients to as low as $50 per fill. Eligibility requires active commercial insurance that covers at least part of the drug's cost. Patients without insurance or with government insurance (Medicaid, Medicare, Tricare) are not eligible for manufacturer copay cards. Those patients often find compounded bremelanotide from a 503A pharmacy to be the most affordable path.

According to a 2023 analysis published in the Journal of Sexual Medicine, cost remains the primary barrier to bremelanotide adherence, with 38% of patients discontinuing within six months citing expense [7].

Blood Pressure Monitoring and Safety Considerations

The FDA label includes a specific warning about transient blood pressure elevation. In the RECONNECT trials, systolic blood pressure increased by a mean of 6 mmHg and diastolic by 3 mmHg within 2 to 3 hours of injection, returning to baseline within 12 hours [2]. This is clinically relevant for women with uncontrolled hypertension, and the label contraindicates use in that population.

Before prescribing, North Carolina clinicians should document a baseline blood pressure. The American College of Obstetricians and Gynecologists (ACOG) has noted that HSDD treatment decisions should incorporate cardiovascular risk assessment, particularly in women over 40 or those with metabolic syndrome [8].

Nausea management is the other practical concern. About 40% of patients experienced nausea in trials, with 13% rating it severe enough to cause treatment discontinuation. Taking bremelanotide on a non-full stomach appears to worsen nausea. Some prescribers recommend a light meal 1 to 2 hours before injection and suggest ondansetron 4 mg as a pretreatment for the first few uses while the body adapts.

Dr. Sheryl Kingsberg, a lead RECONNECT investigator, noted in published commentary: "Most women who experience nausea see it diminish substantially by the third or fourth dose. We counsel patients to commit to at least four to six uses before judging tolerability" [2].

Who Can Prescribe Vyleesi in North Carolina?

North Carolina does not restrict bremelanotide prescribing to a particular specialty. Any provider with prescriptive authority licensed in the state can write the prescription, provided they meet the standard-of-care requirements for diagnosing HSDD.

Physicians (MD/DO): Full independent prescriptive authority. OB/GYNs, primary care physicians, psychiatrists, and sexual medicine specialists all prescribe bremelanotide.

Nurse Practitioners (NP): North Carolina requires NPs to practice under a Collaborative Practice Agreement with a supervising physician. The agreement must authorize prescribing of bremelanotide or the drug class it falls under. NPs in NC gained expanded prescriptive authority under Session Law 2021-129 but still require the collaborative agreement for controlled and non-controlled drugs alike [3].

Physician Assistants (PA): PAs in North Carolina prescribe under physician supervision. The supervising physician's scope must encompass the relevant clinical area. PAs in OB/GYN or primary care settings routinely prescribe medications for sexual health conditions.

Transferring a Vyleesi Prescription to North Carolina

Patients relocating to North Carolina from another state can transfer an existing Vyleesi prescription. North Carolina Board of Pharmacy regulations allow interstate prescription transfers for non-controlled substances. Bremelanotide is not a scheduled controlled substance, so the transfer process is straightforward.

The patient contacts their current pharmacy and requests a transfer to a North Carolina pharmacy. The receiving pharmacist verifies the prescriber's credentials, confirms remaining refills, and processes the transfer. The original prescription record transfers with the fill history intact.

If the original prescriber is not licensed in North Carolina, the patient will need a new prescription from an NC-licensed provider for future refills. Telehealth platforms simplify this: a single video consultation with an NC-licensed prescriber can generate a fresh prescription with refills.

Timeline: How Long Until You Receive Vyleesi in NC?

From initial inquiry to medication in hand, most North Carolina patients can expect the following timeline. A telehealth consultation can be scheduled within 1 to 3 days. Lab work (if not already completed) takes 1 to 3 business days for results. Prescription review and transmission happens within 24 to 48 hours after lab review. Pharmacy fulfillment adds 1 to 5 business days for branded Vyleesi (depending on stock) or 3 to 7 business days for compounded bremelanotide shipped from a 503A pharmacy.

Total elapsed time: roughly 5 to 14 days from first contact to first injection. Patients with recent labs and a prior HSDD diagnosis can compress this to under a week.

Focal Hyperpigmentation and Long-Term Use

The FDA label notes that bremelanotide can cause focal hyperpigmentation, particularly on the face, gingiva, and breasts [1]. In the RECONNECT trials, about 1% of patients developed darkening of skin in these areas. The pigmentation changes are generally not reversible after discontinuation. Prescribers in North Carolina should document baseline skin findings and counsel patients about this risk before initiating therapy.

Long-term safety data beyond 12 months remains limited. The Endocrine Society has called for post-marketing surveillance registries for drugs affecting melanocortin pathways, given theoretical concerns about melanocyte stimulation [9].